Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | MGAM | O43451 | 1/20 | 0.48 |
| ▸ | SI | P14410 | 1/20 | 0.48 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9081933 | 0.87 | CYP1A2 (0.55) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL27934173 | 0.86 | CYP1A2 (0.48) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL14191480 | 0.83 | DGKA (0.45) | ALDH1A1L3MBTL1LMNAMAPT | |
| SCHEMBL11060292 | 0.83 | CYP1A2 (0.45) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL4328506 | 0.83 | ALDH1A1 (0.46) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL13776055 | 0.83 | CYP1A2 (0.50) | CYP1A2GAAMGAMSIMGAM2 | |
| Succinic Acid Diethyl Ester SCHEMBL22780 | 0.83 | GAA (0.67) | CYP1A2GAAMGAMSIMGAM2 | |
| Succinic Acid Diethyl Ester SCHEMBL27768067 | 0.83 | GAA (0.67) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL12873361 | 0.82 | TSHR (0.48) | CYP1A2ALDH1A1CYP4F2CYP4A11TSHR | |
| SCHEMBL1980755 | 0.81 | CYP1A2 (0.44) | CYP1A2GAAMGAMSIMGAM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629465-B2 | Industrial process for preparation of Clopidogrel hydrogen sulphate | IPCA LABORATORIES LTD. (IN) | 2009-12-08 | — | — | US | claimed |
| US-20080097101-A1 | Industrial process for preparation of clopidogrel hydrogen sulphate | IPCA LABORATORIES LIMITED (IN) | 2008-04-24 | — | — | US | claimed |
| EP-1772455-A2 | Industrial process for preparation a polmorph of clopidogrel hydrogen sulphate | IPCA Laboratories Limited (IN) | 2007-04-11 | — | — | EP | claimed |
| WO-2025217212-A1 | MAC1 INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-10-16 | — | — | WO | disclosed |
| CN-107849023-A | Bicyclic lactams and methods of use thereof | 豪夫迈·罗氏有限公司 | 2018-03-27 | — | — | CN | disclosed |
| US-7365221-B2 | Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof | PANACOS PHARMACEUTICALS, INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365221-B2 | Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof | PANACOS PHARMACEUTICALS, INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-20070197646-A1 | SUBSTITUTED TARAXASTANES USEFUL FOR TREATING VIRAL INFECTIONS | ACHILLION PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-20070197646-A1 | SUBSTITUTED TARAXASTANES USEFUL FOR TREATING VIRAL INFECTIONS | ACHILLION PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-5032590-A | Substituted hydroxylamines | BAYER AKTIENGESELLSCHAFT (DE) | 1991-07-16 | — | — | US | disclosed |
| US-4968681-A | Substituted hydroxylamines | BAYER AKTIENGESELLSCHAFT (DE) | 1990-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080097101-A1 | Industrial process for preparation of clopidogrel hydrogen sulphate | PRKD2, PRKCD, HSD3B1 | CYP1A2 108/4885GAA 4075/4885MGAM 1183/4885 |
| US-20070197646-A1 | SUBSTITUTED TARAXASTANES USEFUL FOR TREATING VIRAL INFECTIONS | TARBP1, TSNAX, TARDBP | CYP1A2 535/4885GAA 46/4885MGAM 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.